The battle between the FTC and generic drug company Watson Pharmaceuticals over whether the company engaged in an anti-competitive deal with Frazer, Pa.-based Cephalon continues in a Washington court as the FTC fired back responses defending its actions during the investigations.

After a magistrate judge for the U.S District Court for the District of Columbia, in a rare move, ordered the U.S. Federal Trade Commission to respond to interrogatories by Watson CEO Paul Bisaro about why the FTC was seeking his testimony, the FTC answered the questions and gave a little extra. And Watson quickly issued a response.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]